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Background: In acute HIV-1 infection, STI may induce immunologic control of HIV-1 
replication. Several prospective trials of STI in chronic HIV-1 infection have been less 
encouraging. A previously presented retrospective analysis of our patients showed that in 
those with a significant CD4 increase (>200 cells) on antiretroviral therapy (ART), 2 or 
more interruptions may significantly lower viral set point. This prospective study 
describes STI in a cohort of patients. 
 
Methods: 10 patients with either a positive response to therapy interruption 
retrospectively or those expressing interest in the strategy who met inclusion criteria (VL 
BLQ on ART, good adherence, robust CD4 response) were selected. Interruptions 
analyzed were prospective and supervised. Timing of STI cycles was based on CD4 and 
Viral Load (VL) responses not a predetermined schedule. Data collected included 
demographics, ART, VL, CD4, and illnesses during STI. 
 
Results: Of 7/10 patients with data at 4 weeks off ART, the mean VL was 1.78 log10 
copies/ml below baseline (BL). In 10 patients > 8 weeks off ART, the mean VL was 1.38 
log10 below BL. 7/10 maintained VL <5000 for > 8 weeks off ART (mean 27 weeks, 1 > 
2 years). 4/7 with data during more than one STI showed an increase in time to reach 
5000 copies/ml. None developed resistance-conferring mutations nor HIV-related 
illnesses during interruption. ART regimen or Hepatitis C seropositivity were not 
statistically significant factors affecting response to STI (duration <5000 or ΔVL; 
p>0.05). 
 
Conclusions: Although no consensus exists concerning the effectiveness of STI in 
chronic HIV infection, a majority of our subjects were able to stop ART and maintain 
viral control for a period of time. Closely monitored STI was associated with lowered 
viral set point during the interruption in most cases. A larger prospective study is 
warranted but we recommend future trials measure additional parameters and avoid using 
the same STI schedule for all subjects.  
BACKGROUND 
 
Effective antiretroviral treatment of human immunodeficiency virus-1 (HIV-1) infection 
requires long-term >95% adherence in the face of significant toxicity [1].  Additionally, 
eradication of HIV-1 infection does not appear to be possible with currently available 
agents [2].  Furthurmore, the DHHS guidelines for the treatment of HIV-1 infected adults 
and adolescents have been modified to reserve antiretroviral therapy (ART) until the 
CD4+ T-cell count (CD4) falls to <350 cells/ml [3].  This has led to debate about the 
practicality of the present doctrine of providing continuous ART to patients meeting 
criteria for ART.  A large, ongoing, prospective trial may provide answers to this question 
[4].  Retrospectively, a few studies have attempted to elicit predictors of the ability to 
remain off ART for longer periods during treatment interruptions (TI) [5,6].  However, 
the results have been inconsistent.  It has been shown that TI may induce immunologic 
control of viral replication in acute HIV-1 infection, thus reducing the need for ART in 
this setting [7].  Several trials of structured TI in chronic HIV-1 infection have been less 
encouraging [8-11]. A previously presented retrospective analysis of our patients showed 
that in those with a significant CD4 increase (>200 cells/ml) on ART, 2 or more TI may 
significantly lower the viral set point during the TI [12].  This prospective study describes 






 A prospective study of a select cohort of patients was conducted from 2/99 – 12/01 at 
Bornemann Internal Medicine (BIM), an urban HIV clinic. 
 
 Patients were selected on the basis of a prior positive response to TI (>1 log10 
decrease in rebound viremia during TI as compared to baseline VL) in our 
retrospective study or by expressing interest in STI and meeting the following criteria: 
VL below the level of quantification (BLQ) on ART, good adherence, robust CD4 
response.  BLQ was defined as less than 400 copies HIV-1 RNA per ml plasma (<50, 
if available). 
 
 Treatment interruptions were planned and supervised by the medical provider.  The 
timing of STI cycles was based on CD4 and VL responses not a predetermined 
schedule.  All STI involved simultaneous cessation of the entire antiretroviral regimen 
for greater than seven (7) days. 
 
 Charts were abstracted for the following: baseline study patient demographics, ART 
regimen, treatment duration, VL, CD4, STI duration, and illnesses during STI.
RESULTS 
 
Table 1: Study Patients 
Number of Patients: 10 
Mean Age: 36.3 years 












BLVL:   Mean 
  Median 
106991 copies/ml 
73067 copies/ml 




Table 2: Duration of ART and STI 
Pt. Time on ART 
(weeks) 






% F/U on 
ART 
1 120 30 7.5 150 80.0% 
2 57 18 9.0 75 76.0% 
3 96 19 19.0 115 83.5% 
4 63 11 11.0 74 85.1% 
5 59 73 36.5 132 44.7% 
6 169 13 13.0 182 92.9% 
7 193 32 16.0 225 85.8% 
8 30 107 107.0 137 21.9% 
9 19 15 15.0 34 55.9% 
10 238 47 15.7 285 83.5% 
Mean 104.4 36.5 25.0* 140.9 70.9% 
* Median STI Duration = 11.0 weeks 
 











1 341000 44 <50 504 On ART 







3 9000 484 2856 555 STI 
4 120000 706 151 1089 On ART 
5 39000 580 878 595 STI 
6 53242 359 635 600 On ART 







8 92892 435 4701 608 STI 
9 41700 360 4968 428 STI 
10 235687 611 242 509 On ART 
* Mean CD4 is +132 cells/ml compared to baseline at latest follow-up (p=0.036). 
†
  Started ART at last visit.  Values listed are last VL/CD4 during previous STI. 
 
Table 4: (See next page) 
 
 HAART regimen prior to STI and Hepatitis C Virus 
seropositivity does not affect outcome (duration <5000 
copies/ml plasma or -ΔVL) significantly (p >0.05). 
 
 No patients developed resistance-conferring mutations. 
Table 4:  Individual Patient Results 








At 4* Weeks 
(copies/ml) 
Greatest –ΔVL 
At >8 Weeks 
(copies/ml) 





1 4 1 11 Weeks -2.339 log10 (3 Wks.) -2.357 log10 (11 Wks.) No None 
2 2 0 - -0.473 log10 (4 Wks.) -0.210 log10 (9 Wks.) No (No VL 
<5000)† 
None 
3 1 0 12 Weeks NA** -0.940 log10 (16 Wks.) NA (1 STI) Strep. 
Phayngitis/ 
Pneumonia 
4 1 2 3 Weeks -1.218 log10 (5 Wks.) -1.591 log10 (11 Wks.) NA (No data for 
TI 1,2) 
None 
5 2 3 40 Weeks -1.622 log10 (6 Wks.) -1.989 log10 (32 Wks.) 
-1.406 log10 (42 Wks.) 
Yes None 
6 1 3 9 Weeks -1.311 log10 (5 Wks.) -0.925 log10 (11 Wks.) Yes None 
7 2 0 22 Weeks -2.938 log10 (4 Wks.) -1.425 log10 (22 Wks.) Yes None 
8 1 3 107 Weeks -2.521 log10 (5 Wks.) -2.471 log10 (15 Wks.) 
-2.199 log10 (79 Wks.) 
-1.296 log10 (107 Wks.) 
Yes None 
9 1 0 15 Weeks NA** -0.924 log10 (15 Wks.) NA (1 STI) None 
10 3 3 - NA** -1.012 log10 (8 Wks.) No (No VL 
<5000) 
None 
Mean 1.8 1.5 21.9 Weeks -1.78 log10 -1.38 log10 - - 
* Values ranged from 3-6 weeks. 
**These patients did not have VLs available during the time period specified. 
† VL rebound at 4 weeks was 0.503 log10 lower in STI 2 than STI 1. 
CONCLUSIONS 
 
 STI allowed this select cohort of chronically-infected, HIV-1+ patients to discontinue 
ART for extended periods of time (median 11 weeks, mean 25 weeks, range 4-107 
weeks). One patient (Pt. 8) remains off ART for more than 2 years. 
 
 Most patients maintained VL >1 log10 below baseline at 4 weeks and at >8 weeks during 
STI and <5000 copies/ml for a mean of 21.9 weeks.  4 of 7 patients with data from 
multiple STI showed an increase in time to reach 5000 copies/ml in successive STI.  This 
may be suggestive of an HIV-specific immunologic response.  Immunoproliferative data is 
necessary to corroborate this finding. 
 
 Even in the presence of multiple STI, most patients have improved immunologic status 
measured by CD4 count at latest follow-up as compared to baseline (p = 0.036).  No OIs 
occurred during STI and no cases of acute retroviral syndrome were noted.  Within this 
cohort, taking ART for only a mean of 70.9% of the total follow-up was sufficient to 
preserve and, in most cases, improve immunologic status.  STI also allowed a respite from 
the rigors of ART (pill burden, intense compliance, adverse events). 
 
 At latest follow-up, 6 of 10 patients are on ART with one patient BLQ, 2 approaching 
<50, and 2 patients without data due to starting ART at the last visit.  Patient 6 has had 
persistently detectable, low-level viremia on d4T/ddI/HU, consistent with other patients 
taking this combination [8].  All 4 patients who are in an STI have VL <5000 copies/ml.  
No patients have developed resistance-conferring mutations. 
 
 It should be noted that this is a selected cohort of patients, introducing multiple biases.  It 
was our intent to use this study to evaluate our STI strategy, involving the selection of 
patients with good virologic and immunologic responses to ART and a history of good 
compliance.  Randomization of patients in future trials may not show similar results. 
 
 This cohort had high baseline viral loads and CD4 counts according to current DHHS 
treatment guidelines.  Because treatment was initiated earlier, consistent with guidelines at 
the commencement of this study, future trials will need to address STI in patients initiating 
ART with more progressive disease. 
 
 In summary, a majority of our subjects were able to stop ART and maintain viral control 
for a period of time. Closely monitored STI was associated with lowered viral set point 
during the interruption in most cases.  We recommend that STI timing in future trials be 




1.  Paterson DL, Swindells S, Mohr J, et al.  Adherence to protease inhibitor therapy and 
outcomes in patients with HIV infection.  Ann Intern Med 2000;133:21-30. 
2.  Finzi D, Blankson J, Silliciano JD, et al.  Latent infection of CD4+ T cells provides a 
mechanism for lifelong persistence of HIV-1, even in patients on effective 
combination therapy.  Nat Med 1999;5(5):512-517. 
3.  Centers for Disease Control and Prevention.  Guidelines for using antiretroviral 
agents among HIV-infected adults and adolescents.  Recommendations of the Panel 
on Clinical Practices for Treatment of HIV.  MMWR Recomm Rep.  2002 May 
17;51(RR-7):1-55. 
4.  NIAID, Division of AIDS.  A Large, Simple Trial Comparing Two Strategies for 
Management of Anti-retroviral Therapy (The SMART Study, CPCRA 065). Ver. 1.0. 
2001 Sep 11, Accessed: 2002 June 11 http://www.smart-trial.org. 
5.  Parish M, Tarwater P, Raines, C, Gallant JE. Prolonged treatment interruption after 
immunologic response to HAART [Abstract ThOrB1439]. In: Program and Abstracts 
of the XIV IAC, July 7-12, 2002; (Barcelona, Spain).  International AIDS Society.  
6.  Tebas P, Henry K, Mondy K, et al. Effect of Prolonged Discontinuation of Successful 
Antiretroviral Therapy on CD4+ T Cell Decline in Human Immunodeficiency Virus-
Infected Patients: Implications for Intermittent Therapeutic Strategies.  J Infect Dis. 
2002;186(6):851-4. 
7.  Altfield M, Walker BD.  Less is more? STI in acute and chronic HIV-1 infection.  Nat 
Med 2001;7:881-84. 
8.  Lori F, Foli A, Maserati R, et al.  Control of HIV During a Structured Treatment 
Interruption in Chronically Infected Individuals with Vigorous T Cell Responses.  
HIV Clin Trials 2002;3(2):115-124. 
9.  Bonhoeffer S, Rembiszewski M, Ortiz GM, et al. Risks and benefits of structured 
antiretroviral drug therapy interruptions in HIV-1 infection.  AIDS 2000;14:2313-22. 
10. Ruiz L, Martinez-Picado J, Romeu J, et al. Structured treatment interruption in 
chronically HIV-1 infected patients after long-term viral suppression.  AIDS 
2000;14:397-403. 
11. Neumann AU, Tubiana R, Calvez V, et al. HIV-1 rebound during interruption of 
highly active antiretroviral therapy has no deleterious effect on reinitiated treatment.  
AIDS 1999;13:677-83. 
12. Yozviak JL, Doerfler RE, Woodward WC. Intermittent antiretroviral therapy (ART) 
can induce reduction of viral rebound during ART-interruption [abstract 236].  In: 
Program and Abstracts of the 7th European Conference on Clinical Aspects and 
Treatment of HIV-Infection, 1999 Oct 23-7; (Lisbon, Portugal).  European AIDS 
Clinical Society; 1999: 29. 
